Preeclampsia is a progressive and pregnancy-specific disorder and it affects multiorgan systems. Although the pathophysiology of preeclampsia is still unknown, it involves both maternal and fetal/placental factors. Endothelial cell damage and impaired endothelial cell function play an important role in the development of preeclampsia. Adipokines have role in many pathophysiological processes in the body. Subfatin is a newly discovered adipokine, if dysfunctional may cause endothelial damage. In this study it was aimed to evaluate the relationship between subfatin and preeclampsia. This study was designed as prospective case-control study. Fifty-six women, 28 women with preeclampsia and 28 normotensive women who had delivered between gestational age of 37th and 41th weeks with singleton pregnancies in a tertiary reference hospital was included. ROC analysis was used to calculate the predictive value of Subfatin for preeclampsia. There was no statistically significant difference in terms of age, BMI, gravidity and parity between groups. Mean systolic (157.14±15.36 vs 113.21±6.55 mm/Hg, p < 0.001) and diastolic blood pressures (95.71±8.35 vs 73.21±5.47 mm/Hg, p < 0.001) were observed higher in case group than control group. Subfatin level of control group was found higher than case group and this difference was statistically significant (58.89±17.66 vs 31.85±16.58 ng/mL, p < 0.001). According to ROC analyzes; cutoff value of Subfatin level ≤ 43 ng/mL with 78.6% sensitivity and 71.4% specificity was found significant for case group. AUC was calculated as 0.872 (p < 0.001). Binary logistic regression analysis showed that low levels of subfatin was related with preeclampsia (Odds Ratio: 0.910, 95% CI: 0.866-0.955, p < 0.001). subfatin may be helpful in predicting preeclampsia development in pregnant women. Low levels of subfatin may be warning sign before its development.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Research Article |
Authors | |
Early Pub Date | October 6, 2023 |
Publication Date | September 30, 2023 |
Submission Date | March 21, 2023 |
Acceptance Date | April 7, 2023 |
Published in Issue | Year 2023 Volume: 40 Issue: 3 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.